Controlled Release Delivery Conference 2018

SMi Group21 - 22 March, London, UK.
An industry-leading show, SMi have been running this conference for 15 years - a testament of how vital this particular focus is to the biotech and pharma sector. As physicians and scientists continue to find strategies to assist in simplifying treatment schedules for patients, a pharma focus continues to move towards innovative controlled release technologies to improve drug transport to target.

Moreover, with the global oral controlled release drug delivery technology market expected to expand at 7.2% CAGR between 2017-2027 (with an estimated revenue of US$50B by 2027), now is the time to get ahead of the game by exploring and understanding innovations in drug delivery, nanoparticles/nanomedicine & QbD, CNS drug delivery and therapeutic application.

Who will be speaking?

  • Howard Stevens, Emeritus Professor, University of Strathclyde (CHAIRMAN)
  • Joël Richard, Senior Vice President, Peptides Development, Ipsen (CHAIRMAN)
  • Mohamed Albed Alhnan, Senior Lecturer, University of Central Lancashire
  • Pavel Farkas, Senior Director - Biopharmaceutics/ Clinical Development, PLIVA
  • Barry Friend, Sr. Technical Manager, Colorcon
  • Sebastian Schwier, Project Director / Int. Technical Project Leader, ‎Grünenthal
  • Karsten Lindhardt, CSO, Head R&D, Egalet
  • Teofilo Vasconcelos, Formulation Manager, Bial
  • Guillaume Saint-Pierre, Chief Executive Officer and Cofounder, PeptiGelDesign

Highlights this March 2018

  • Understand the impact of the current EU Guideline on clinical evaluation of modified release drugs from a pharmaceutical perspective, with a talk from PLIVA
  • Discover new technologies and innovations for the development of Controlled Release drugs including Lipid-composite microparticles, Molecular Envelope Technology (MET) nanoparticles and Abuse-Deterrent Formulations
  • Focus on Successful Oral Technologies progressing in the clinic, with talks discussing lessons learned from clinical studies
  • Learn about the advances and challenges in Paediatric controlled release formulations, including taste-masking and oral formulation challenges
  • ...and more.

For further information and to register, please visit:
https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...